Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Rectal Cancer

Rectal Cancer

Rectal Cancer: A serious and often complex malignant neoplasm originating in the rectum, the final segment of the large intestine.
Early detection and appropriate treatment are crucial for improved patient outcomes.
PubCompare.ai's AI-driven platform can help optimize your rectal cancer research by enabling you to easily locate the most relevant protocols from literature, pre-prints, and patents.
With advanced comparisons, you can identify the best protocols and products to enhance the reproducibility and accuracy of your studies.
Leverage the power of PubCompare.ai to take your rectal cancer reseach to the next level.

Most cited protocols related to «Rectal Cancer»

1
Colorectal Cancer Patient Cohort Analysis
The French national Cartes d'Identité des Tumeurs (CIT) program involves a multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers. Fresh-frozen primary tumor tissue samples were retrospectively collected at the Institut Gustave Roussy (Villejuif), the Hôpital Saint Antoine (Paris), the Hôpital Européen Georges Pompidou (Paris), the Hôpital de Hautepierre (Strasbourg), the Hôpital Purpan (Toulouse), and the Institut Paoli-Calmettes (Marseille), and prospectively collected at the Centre Antoine Lacassagne (Nice). Patients who received preoperative chemotherapy and/or radiation therapy and those with primary rectal cancer were excluded from this study. Clinical and pathologic data were extracted from the medical records and centrally reviewed for the purpose of this study. Patients were staged according to the American Joint Committee on Cancer tumor node metastasis (TNM) staging system [2] and monitored for relapse (distant and/or locoregional recurrence; median follow-up of 51.5 mo). Patient and tumor characteristics are summarized in Table 1 and detailed in Table S1.
Of the 750 tumor samples of the CIT cohort, 566 fulfilled RNA quality requirements for GEP analysis (Figure S1). The 566 samples were split into a discovery set (n = 443) and a validation set (n = 123), well balanced for the main anatomoclinical characteristics (Table 1). The validation set also included 906 CC samples available from seven public datasets (GSE13067, GSE13294, GSE14333, GSE17536/17537, GSE18088, GSE26682, and GSE33113). These datasets corresponded to all available public datasets fulfilling the following criteria: available GEP data obtained using a similar chip platform (Affymetrix U133 Plus 2.0 chips) with raw data CEL files, and tumor location and either common DNA alteration (n = 457) and/or patient outcome (n = 449) data available. Within the discovery (n = 443) and the validation (n = 1,029) sets, 359 and 416 patients with stage II–III CC and documented relapse-free survival (RFS) were available for survival analysis, respectively (Figure S1). The dataset from The Cancer Genome Atlas (TCGA) [13] (link), although obtained using a non-Affymetrix platform and therefore analyzed separately, was added to the validation set because of the extensive DNA alteration annotations provided for 152 CC samples.
Marisa L., de Reyniès A., Duval A., Selves J., Gaub M.P., Vescovo L., Etienne-Grimaldi M.C., Schiappa R., Guenot D., Ayadi M., Kirzin S., Chazal M., Fléjou J.F., Benchimol D., Berger A., Lagarde A., Pencreach E., Piard F., Elias D., Parc Y., Olschwang S., Milano G., Laurent-Puig P, & Boige V. (2013). Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine, 10(5), e1001453.
Publication 2013
DNA Chips Freezing Genome Joints Malignant Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy Rectal Cancer Recurrence Relapse Tissues
2
Contouring Consensus for Rectal Cancer

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
ARID1A protein, human Arteries Blood Vessel Cancers, Anal Conferences Groin Ilium Intestines Intestines, Small Medical Devices Muscle Tissue Nodes, Lymph Patients Physiologic Calcification Radiotherapy Rectal Cancer Rectum Sacrum Skin styrofoam X-Ray Computed Tomography
3
Consensus on Rectal Cancer Imaging
Similar to the methodology adopted for the 2012 consensus meeting [1 (link)] an adaptation of the RAND-UCLA Appropriateness Method (RAM) was chosen [5 ], which combines postal and face-to-face rounds. For the present update, the process can be summarised as follows:

Literature review

Two of the organising members (DL, MM) in consensus searched current literature to identify newly available indexed scientific evidence regarding rectal cancer imaging, published following the 2012 meeting, which was used to update the questionnaires used for the 2012 consensus meeting by addition of topics not discussed previously.

Update of the questionnaires

Updated questionnaires were constructed by two organising members (DL, MM), in consultation with two others (SB, RB). The original 2012 questionnaire comprised 236 items. Seventeen new items were added, which mainly concerned the current use of tumour node metastasis (TNM) staging systems [6 , 7 ], the staging of tumours extending into the anal canal, criteria for nodal staging, use of structured reporting, and protocols for acquisition and evaluation of DWI. The questionnaire was divided into part A and part B. Part A included items reaching consensus in the 2012 meeting. Panellists were asked to indicate for each item whether they still agreed with the consensus statement reached previously or whether the item should be re-discussed. Part B combined items that did not reach consensus in 2012 with the additional 17 items derived from the updated literature review. All items were scored binomial (YES/NO; still valid or to be rediscussed) or ordinal (e.g. not recommended, recommended, mandatory), according to the individual item in question. Panellists were instructed to select ‘Mandatory’ for items that they considered were mandatory, ‘Recommended’ for items that they believed to be of additional benefit but that were not mandatory, and ‘Not recommended’ for items that they believed were not required and of no additional value.

Panel selection

The panel consisted of the same 14 panellists (BB, LC-S, HF, MG, SG, SH, CH, SHK, AL, AM, SR, JS, ST, MT) who participated in the 2012 consensus meeting. All were leading abdominal radiologists and members of ESGAR with recognised expertise and a publication track record within the field of rectal cancer imaging. The panel also included two non-voting Chairs (LB, RB) and three non-voting organising members (DL, MM, SB).

Questionnaire completion before the face-to-face meeting

Questionnaires were emailed to panellists on 11 May 2016. Panellists rated items independently with no interaction amongst each other and returned completed questionnaires by email.

Data analysis from questionnaire round

For each rated item from the electronic questionnaire round, two non-voting members (DL,MM) assessed whether or not consensus (defined as ≥ 80 % agreement) was reached.

Face-to-face panel meeting

A face-to-face panel meeting took place during the annual ESGAR meeting, Prague, 15 June 2016. Twelve of the 14 panellists attended. The meeting was moderated by two non-voting Chairs, RB and LB. Two non-contributing (non-voting) observers (DL, MM) documented key points of discussion and outcomes from the voting rounds. The results from the electronic questionnaire round formed the basis for discussion. Discussion included all items from the part A questionnaire selected for re-discussion by at least 20 % of the panellists in addition to all items from questionnaire part B that failed to reach consensus after the email round. Some items were rephrased or merged after face-to-face panel discussion (to reduce ambiguity or overlap) and as a result seven previously included items were discarded. After each item was discussed, panellists were asked to vote (using the same scoring systems as in the electronic round). Thirty items were not discussed face-to-face due to time constraints and were voted on by email subsequently.

Data analysis and reporting

Data from both electronic and face-to-face rounds were collected and descriptive metrics calculated by DL and MM. Each item was ultimately classified as: (1) ‘Appropriate’ with ≥ 80 % agreement, (2)’ Inappropriate’ with ≥ 80 % agreement or (3; Uncertain (no consensus, i.e. < 80 % agreement).

Beets-Tan R.G., Lambregts D.M., Maas M., Bipat S., Barbaro B., Curvo-Semedo L., Fenlon H.M., Gollub M.J., Gourtsoyianni S., Halligan S., Hoeffel C., Kim S.H., Laghi A., Maier A., Rafaelsen S.R., Stoker J., Taylor S.A., Torkzad M.R, & Blomqvist L. (2017). Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. European Radiology, 28(4), 1465-1475.
Publication 2017
Abdomen Acclimatization Anal Canal Face Neoplasm Metastasis Neoplasms Radiologist Rectal Cancer
4
Colorectal Cancer Epidemiologic Study
We used data from two prospective cohort studies, the Nurses’ Health Study (NHS, involving 121,700 women who were enrolled in 1976) and the Health Professionals Follow-up Study (HPFS, involving 51,500 men who were enrolled in 1986).22 (link),23 (link) Every 2 years, participants were sent follow-up questionnaires to update information on lifestyle factors and to identify newly diagnosed cancers and other diseases. The National Death Index was used to ascertain deaths of study participants. The cause of death was assigned by study physicians. Paraffin-embedded tissue blocks were collected from hospitals where participants with colorectal cancer had undergone colorectal resection or endoscopic biopsy (for preoperatively treated rectal cancer). Tumor-tissue data, information on aspirin use, and survival data were available for 1097 patients with colorectal cancer that was diagnosed before July 1, 2006. Among these patients, we used data from 964 patients for whom information about the presence or absence of PIK3CA mutation, based on analysis of tumor tissue, was available. Patients were followed until death or January 2011, whichever came first.
Written informed consent was obtained from all study participants. Tissue collection and analyses were approved by the human subjects committees at the Harvard School of Public Health and Brigham and Women's Hospital. The last two authors were responsible for the study concept and design. All authors acquired, analyzed, and interpreted the data. The first two authors and the last two authors take responsibility for the integrity of the data and the accuracy of the data analysis and vouch for the fidelity of the study to the protocol.
Liao X., Lochhead P., Nishihara R., Morikawa T., Kuchiba A., Yamauchi M., Imamura Y., Qian Z.R., Baba Y., Shima K., Sun R., Nosho K., Meyerhardt J.A., Giovannucci E., Fuchs C.S., Chan A.T, & Ogino S. (2012). Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. The New England journal of medicine, 367(17), 1596-1606.
Publication 2012
Aspirin Biopsy Colorectal Carcinoma Endoscopy Health Personnel Homo sapiens Malignant Neoplasms Mutation Neoplasms Nurses Paraffin Patients Physicians PIK3CA protein, human Rectal Cancer Tissues Woman
5
Comprehensive Colorectal Cancer Cohort Study
We utilized the database of two independent, prospective cohort studies; the Nurses’ Health Study (N=121,701 women followed since 1976), and the Health Professionals Follow-up Study (N=51,529 men followed since 1986).[27 (link), 28 (link)] Every 2 years, participantshave been sent follow-up questionnaires to update informationon potential risk factors and to identify newly diagnosed cancers in themselves and their first degree relatives. In addition, we searched the National Death Index for those who died of colorectal cancer. Our study physicians reviewed medical records and obtained information on disease stage and tumor location (rectum, rectosigmoid, sigmoid colon, descending colon, splenic flexure, transverse colon, hepatic flexure, ascending colon, and cecum). We collected paraffin-embedded tissue blocks from hospitals where patients underwent tumor resections. We collected diagnostic biopsy specimens for rectal cancer patients who received preoperative treatment, in order to avoid artifacts or bias introduced by treatment. Based on availability of adequate tissue specimens and follow-up data, a total of 1443 colorectal cancer cases (diagnosed up to 2006) were included (Tables 1–2). Among our cohort studies, there was no significant difference in demographic features between cases with tissue available and those without available tissue.[27 (link)] This current study represents a new analysis of tumor molecular features along the detailed bowel subsites on the existing colorectal cancer database that has been previously characterized for CIMP, MSI, LINE-1 methylation and BRAF and KRAS mutations.[29 (link), 30 (link)] Informed consent was obtained from all study subjects. This study was approved by the Harvard School of Public Health and Brigham and Women’s Hospital Institutional Review Boards.
Yamauchi M., Morikawa T., Kuchiba A., Imamura Y., Qian Z.R., Nishihara R., Liao X., Waldron L., Hoshida Y., Huttenhower C., Chan A.T., Giovannucci E., Fuchs C.S, & Ogino S. (2012). Assessment of Colorectal Cancer Molecular Features along Bowel Subsites Challenges the Conception of Distinct Dichotomy of Proximal vs. Distal Colorectum. Gut, 61(6), 847-854.
Publication 2011
Biopsy BRAF protein, human Cardiac Arrest Cecum Colic Flexure, Right Colon, Ascending Colon, Descending Colorectal Carcinoma Ethics Committees, Research Health Personnel Inpatient Intestinal Cancer K-ras Genes Left Colic Flexure LINE-1 Elements Malignant Neoplasms Methylation Mutation Neoplasms Neoplasms by Site Nurses Paraffin Patients Physicians Rectal Cancer Rectum Sigmoid Colon Tissues Transverse Colon Woman

Most recents protocols related to «Rectal Cancer»

1
Adult Rectal Cancer Surgical Techniques
Inclusion criteria were as follows: (1) the study participants were adults with rectal cancer who underwent surgical treatment, (2) at least two of the anastomosis techniques (CJP, SCA, TCP, SEA) were included in the study, (3) at least one of the primary outcome indicators (anastomotic leakage and defecation frequency) was included, and (4) the research type was English RCTs. Exclusion criteria were as follows: (1) non-randomized controlled trials, including reviews, retrospective studies, commentaries, and meta-analyses; (2) lack of available data or outcomes; and (3) duplicate publication of content. Two authors (MX and YZ) independently reviewed the entire text in accordance with the inclusion and exclusion criteria, consulted a third author (CWL) in case of disagreement, and decided on the inclusion of eligible studies at a conference.
Liu H., Xiong M., Zeng Y., Shi Y., Pei Z, & Liao C. (2023). Comparison of complications and bowel function among different reconstruction techniques after low anterior resection for rectal cancer: a systematic review and network meta-analysis. World Journal of Surgical Oncology, 21, 87.
Publication 2023
Adult Anastomotic Leak Conferences Defecation Operative Surgical Procedures Rectal Cancer Surgical Anastomoses
2
Longitudinal Study of Colon and Rectal Cancer
This was a longitudinal prospective observational analytic cohort study that includes patients from nineteen public hospitals representing nine provinces in Spain, all of which operate under the Spanish National Health Service (SNHS), which is responsible for most of the country’s population, with a planned patient follow-up period of 5 years. Patients with colon or rectal cancer scheduled to undergo surgery between June 2010 and December 2012 were informed of the aims of the study and invited to participate. Only patients who provided written informed consent were allowed to enroll in the study. The study was approved by the Basque Ethics Committee (Approval Number: 11/23/2010 and PI2014084) and all study data were kept confidential. Patients were deemed eligible for this study if they were on the surgical waiting list of one of the participating hospitals and had a diagnosis of surgically resectable colon or rectal cancer. Exclusion criteria were in situ cancer, an unresectable tumor, terminal disease, inability to respond to questionnaires for any reason, and any severe mental or physical conditions that might prevent the patient from responding to questionnaires, as well as failure to consent to participate. Detailed information of the protocol has been published elsewhere [20 ].
Orive M., Barrio I., Lázaro S., Gonzalez N., Bare M., de Larrea N.F., Redondo M., Cortajarena S., Bilbao A., Aguirre U., Sarasqueta C, & Quintana J.M. (2023). Five-year follow-up mortality prognostic index for colorectal patients. International Journal of Colorectal Disease, 38(1), 64.
Publication 2023
Carcinoma in Situ Colon Diagnosis Ethics Committees Health Services, National Hispanic or Latino Inpatient Neoplasms Operative Surgical Procedures Patients Physical Examination Rectal Cancer
3
Laparoscopic Radical Resection for Upper Rectal and Sigmoid Colon Cancer
From January 2017 to December 2021, patients underwent laparoscopic radical resection in treatment for upper rectal cancer and sigmoid colon cancer at the National Cancer Center were reviewed. Patients who underwent laparoscopic surgery with natural orifice extraction were assigned to NOSES group while patients who performed conventional laparoscopic surgery with abdominal auxiliary incision were assigned to LAP group. The inclusion criteria were as follows: (1) aged between 18 and 75 years; (2) cT stage 1–3 (3) without distant metastasis. The exclusion criteria were: (1) complicated with other malignant tumors (2) emergency surgery for acute intestinal obstruction, perforation or bleeding. Finally, 186 patients who underwent NOSES and 274 who underwent LAP were enrolled. Propensity score matching (PSM) was used to balance the baseline data between the two groups. Propensity scores were matched 1:1 based on age, gender, body mass index (BMI), American Society of Anaesthesiologists (ASA) score, preoperative chemotherapy, tumor location, tumor differentiation, T stage, N stage, and tumor size. Finally, 144 patients were assigned to the NOSES group while 144 patients were assigned to the LAP group (Figure 1).
Preoperative assessment for all patients included laboratory examination, colonoscopy with biopsy, abdominal CT scan and pelvic magnetic resonance imaging. Tumor staging was evaluated according to the American Joint Committee on Cancer (AJCC, eighth edition) staging system. Patients with clinical stage II and III received preoperative chemoradiotherapy followed by surgery 6 weeks later. All patients received mechanical bowel preparation before surgery, and intravenous antibiotic profilaxis were administered during perioperative period. Postoperatively, patient-controlled analgesia (PCA) was administered to all patients for pain management, and additional nonsteroidal and opioid analgesics were administered intravenously as required. Pain scores were assessed once daily with a validated visual analogue scale (VAS), ranging from 0 to 10, with 0 representing no pain and 10 representing the worst conceivable pain. All patients signed the written informed consent and complied with the Declaration of Helsinki. This retrospective study was approved by the Institutional Review Board Committee of the Cancer Hospital at the Chinese Academy of Medical Sciences (No. 18-015/1617).
Zhao F., Zhao W., Xiao T., Wang Z., Huang F., Xing W, & Liu Q. (2023). Evaluating short-term and survival outcomes of natural orifice specimen extraction surgery for colorectal cancer: A single-centre retrospective study. Frontiers in Surgery, 10, 1078316.
Publication 2023
Abdomen Analgesics, Opioid Anesthesiologist Antibiotics Biopsy Cancer of Sigmoid Chemoradiotherapy Chinese Colonoscopy Emergencies Ethics Committees, Research Gender Index, Body Mass Intestinal Obstruction Intestines Joints Laparoscopy Malignant Neoplasms Management, Pain Neoplasm Metastasis Neoplasms Neoplasms by Site Nose Operative Surgical Procedures Pain Patient-Controlled Analgesia Patients Pelvis Pharmacotherapy Rectal Cancer Surgical Procedures, Laparoscopic Visual Analog Pain Scale X-Ray Computed Tomography
4
Identifying Rectal Cancer Risk Groups
To further validate the reliability of discriminating patients with rectal cancer into two subgroups based on the three m5C regulatory genes, DEGs were identified through R package limma between the low- and high-risk groups. Furthermore, univariate Cox regression analysis was carried out by R package survival to filter prognostic genes on the basis of DEGs. Ultimately, unsupervised clustering analysis was conducted by using R package ConsensuClusterPlus, which was repeated 1,000 times to identify different risk gene clusters (44 (link)).
Zhang R., Gan W., Zong J., Hou Y., Zhou M., Yan Z., Li T., Lv S., Zeng Z., Wang W., Zhang F, & Yang M. (2023). Developing an m5C regulator–mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. Frontiers in Immunology, 14, 1054700.
Publication 2023
Gene Clusters Genes Genes, Regulator Patients Population at Risk Rectal Cancer
5
Retrospective Rectal Cancer TMA Analysis
From Superbiotek in Shanghai, China (#REC1601), we acquired a TMA of 80 paired rectal cancers and corresponding normal tissues. Surgical samples from the patients were taken between May 2008 and December 2012 through operations. The patients’ median survival duration was 81.5 months, ranging from 14 to 130 months. For every case, clinicopathological information including overall survival time, survival status, age, gender, tumor size, pathological T, N, and M stage, and grade was accessible. Based on this commercial TMA, we conducted a retrospective analysis.
For immunohistochemistry (IHC) process, the TMA slides were deparaffinized, rehydrated, and incubated by 3% hydrogen peroxide to block the endogenous peroxidase activity for 10 min at room temperature. Antigens were restored by boiling in a pressure cooker containing sodium citrate buffer for 90 s. The slides were incubated in bovine serum albumin (BSA) for 30 min to reduce nonspecific background. Then, they were incubated with rabbit monoclonal NSUN4 antibody (HPA028489, Sigma), NSUN7 antibody (HPA020653, Sigma), and DNMT1 antibody (HPA002694, Sigma) at 4°C overnight. Next, secondary antibody was incubated with the slides for 1 h at 37°C. Finally, the slides were developed in 3, 3’-diaminobenzidine (DAB) and stained with hematoxylin.
The slides were assessed digitally with the APERIO ScanScope (Leica Biosystems, Germany) and the APERIO ImageScope (Leica Biosystems, Germany) using the positive pixel counting algorithm. The IHC staining results were interpreted by both the intensity of staining and the staining positive area. Each sample was assigned a score according to the intensity of the staining (0 = no staining; 1 = weak staining; 2 = moderate staining; and 3 = strong staining) and the proportion of stained cells (0 = 0%; 1 = 1%–25%; 2 = 25%–50%; 3 = 50%–75%; 4 = 75%–100%). The final score was calculated as the staining intensity multiplying positive area score, ranging from 0 to 12. The IHC results of TMA-rectal cancer were independently reviewed by two experienced pathologists who were blinded to the clinical parameters.
Zhang R., Gan W., Zong J., Hou Y., Zhou M., Yan Z., Li T., Lv S., Zeng Z., Wang W., Zhang F, & Yang M. (2023). Developing an m5C regulator–mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. Frontiers in Immunology, 14, 1054700.
Publication 2023
Antigens Buffers Cardiac Arrest Debility Division Phase, Cell DNMT1 protein, human Gender Immunoglobulins Immunohistochemistry Monoclonal Antibodies Neoplasms Operative Surgical Procedures Pathologists Patients Peroxidase Peroxide, Hydrogen Pressure Rabbits Rectal Cancer Serum Albumin, Bovine Sodium Citrate Tissues

Top products related to «Rectal Cancer»

1
Nexus expression 3 by BioDiscovery
Sourced in United States
The Nexus Expression 3 software is a bioinformatics tool designed for gene expression analysis. It is a comprehensive software package that enables the processing, visualization, and statistical analysis of gene expression data from various high-throughput technologies, such as microarrays and RNA-sequencing.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
4
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
5
Sw1463 by American Type Culture Collection
Sourced in United States, Germany, Australia
The SW1463 is a laboratory equipment product offered by American Type Culture Collection. It is a specialized piece of equipment designed for specific functions within a laboratory setting. The core function of the SW1463 is to facilitate certain laboratory processes, but a detailed description cannot be provided while maintaining an unbiased and factual approach without extrapolation.
6
Sw837 by American Type Culture Collection
Sourced in United States
The SW837 is a laboratory centrifuge designed for general-purpose applications. It features a compact and durable construction, quiet operation, and a wide range of speed and acceleration options. The SW837 is suitable for a variety of sample processing tasks in life science research and clinical laboratories.
7
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
8
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
9
Hct116 by American Type Culture Collection
Sourced in United States, China, Germany, United Kingdom, Japan, Australia, France, Israel, Spain, Poland, Italy
The HCT116 cell line is a human colorectal carcinoma cell line that is widely used in research. It is a commonly used model system for studying various aspects of cancer biology and drug development.

More about "Rectal Cancer"

Rectal Carcinoma: Rectal cancer is a serious and often complex malignant neoplasm originating in the rectum, the final segment of the large intestine.
Early detection and appropriate treatment are crucial for improved patient outcomes.
Also known as colorectal cancer or bowel cancer, it can present with symptoms like rectal bleeding, change in bowel habits, and abdominal pain.
Researchers can leverage advanced tools like PubCompare.ai to optimize their rectal cancer studies.
The AI-driven platform enables easy access to the most relevant protocols from literature, preprints, and patents.
With features like advanced comparisons, users can identify the best protocols and products to enhance the reproducibility and accuracy of their experiments.
When conducting rectal cancer research, it's important to utilize the right cell lines and culture conditions.
Commonly used cell lines include HCT116, SW1463, and SW837, which can be cultured in media like DMEM supplemented with fetal bovine serum (FBS) and antibiotics like penicillin/streptomycin.
Optimizing these factors can help improve the reliability and translatability of the study findings.
By leveraging the power of PubCompare.ai and employing best practices in cell culture and experimental design, researchers can take their rectal cancer research to the next level, leading to advancements in early detection, treatment, and patient outcomes.